Navigation Links
Former Deputy Commissioner of FDA Highlights Value of Small Distributors
Date:12/7/2011

ting product, and often times they have to acquire the product at a much higher price than what GPO might acquire it at," Gottlieb said. "I raise this just because there has been a lot of discussion about the so-called gray market and profiteering, but a lot of the small distributors who are acquiring the drugs at higher prices – and significantly higher prices – and then selling obviously them at higher prices as well, are performing an important market-clearing function."

Gottlieb's comments highlight the vital role small distributors play in health care – a role on which the National Coalition of Pharmaceutical Distributors has been working to educate people for several months.

About NCPD

The National Coalition of Pharmaceutical Distributors is a national trade association representing the wellbeing and interests of the independent and specialty pharmaceutical distribution industry. NCPD is dedicated to securing the pharmaceutical supply chain and is aggressively working to help enact federal legislation to revamp the nation's chain of custody laws for prescription pharmaceutical products.


'/>"/>
SOURCE National Coalition of Pharmaceutical Distributors
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Michigan Life Science and Innovation Center Opens in Former Pfizer Facility
6. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
7. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
8. Former Miss USA Shawnae Jebbia Shines with Siemens Pure
9. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
10. Former Air Force Surgeon General Joins Integrated Medical Systems Advisory Board
11. SCAI Statement on the Hospitalization of Former President Bill Clinton
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Cancer patients in the west ... state-of-the-art cancer treatment closer to home when a new radiotherapy ... Varian Medical Systems (NYSE: VAR ) has been ... placed in June for four TrueBeam™ medical linear accelerators. ... fast and efficient radiotherapy and radiosurgery treatments, will replace older ...
(Date:7/24/2014)... Second Quarter and Recent Highlights: , Appointed Pat ... 2, 2014 , Product revenues grew 12 percent ... revenues grew 14 percent year-over-year to $15.3 million ... to $1.1 million , HeRO ® Graft ... , Tissue processing revenues decreased 6 percent year-over-year to ...
(Date:7/24/2014)... Quebec , July 24, 2014 ... VRX ) (TSX:VRX) announced today that it has ... marches financiers ("AMF") regarding Allergan, Inc.,s (NYSE: ... and to negatively influence the market price of ... and misleading statements regarding Valeant,s business despite Valeant,s ...
Breaking Medicine Technology:Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6
... , GUANGZHOU, China, Nov. ... ("China Medicine" or "the Company"), a developer,and a leading ... nutritional and dietary supplements, and,medical devices and medical formulations, ... Third Quarter 2009 Highlights:, ...
... LAIYANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, ... pharmaceutical company with its principal operations in the People,s,Republic of ... at 9:00 a.m. Eastern Time on Wednesday, November 18, 2009 ... 2010. , Conference Call , ...
Cached Medicine Technology:China Medicine Announces Strong Third Quarter 2009 Results 2China Medicine Announces Strong Third Quarter 2009 Results 3China Medicine Announces Strong Third Quarter 2009 Results 4China Medicine Announces Strong Third Quarter 2009 Results 5China Medicine Announces Strong Third Quarter 2009 Results 6China Medicine Announces Strong Third Quarter 2009 Results 7China Medicine Announces Strong Third Quarter 2009 Results 8China Medicine Announces Strong Third Quarter 2009 Results 9China Medicine Announces Strong Third Quarter 2009 Results 10China Medicine Announces Strong Third Quarter 2009 Results 11China Medicine Announces Strong Third Quarter 2009 Results 12China Medicine Announces Strong Third Quarter 2009 Results 13China Medicine Announces Strong Third Quarter 2009 Results 14China Medicine Announces Strong Third Quarter 2009 Results 15Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010 2
(Date:7/24/2014)... (PRWEB) July 24, 2014 "My child ... know until morning," said an inventor from Cynthiana, Ky. ... can cause seizures, brain damage, hearing loss, vision problems ... would have alerted me to the fever immediately." , ... to continuously monitors the child’s temperature. The unit alerts ...
(Date:7/24/2014)... drinking is associated with upsurges in hospital admissions among ... Ontario, Canada is published online today in the scientific ... of Northern British Columbia Associate Professor of Psychiatry Dr. ... Ontario over a five-year period (2002-07) involving people aged ... the week in which Ontarians turned 19 the ...
(Date:7/24/2014)... are often slow and time-consuming. Therefore, development of ... is very important for improving food safety. , ... Institute, has studied new methods of characterising Salmonella ... in water, feed and food samples. , The ... which factors in pork meat processing may contribute ...
(Date:7/24/2014)... Brightree® , the leading provider ... solutions for the post-acute care industry, announced today ... the nation’s largest family-owned providers of prosthetics, orthotics, ... as its billing and business management platform ... – including business management and document management ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 July ... $138,000 in sealant and anesthesia reversal products to ... to help save young smiles. The donation of ... and Oraverse® was distributed to America’s ToothFairy Affiliate ... with vital oral health services. The America’s ToothFairy ...
Breaking Medicine News(10 mins):Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 2Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 3Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 4Health News:Septodont Donation Helps Children in Need 2
... Investigators at Hospital for Special Surgery, collaborating with researchers ... a gene called interferon regulator factor-8 (IRF-8) is involved ... disease), rheumatoid arthritis and osteoporosis. The study, which will ... the journal Nature Medicine , could lead to ...
... , , , ... Boehringer Ingelheim today announced that results from the RE-LY(R) (Randomized Evaluation ... largest atrial fibrillation (AF) outcomes trial ever conducted(1) (18,113 patients in ... the European Society of Cardiology Congress and published online in the ...
... , , WILMINGTON, Del., Aug. 30 ... the phase III head to head trial, PLATO (A Study of ... that ticagrelor (BRILINTA(TM)) has achieved greater efficacy in the primary endpoint, ... (9.8% vs. 11.7% at 12 months; 16% RRR; 95% CI, 0.77 ...
... watched by typical U.S. teens, analysis finds , FRIDAY, ... attract a significant proportion of teenage viewers are also ... research has found. , Using Nielsen Media Research advertising ... aired on cable TV from 2001 through 2006. The ...
... ... upheld to more stringent standards, including medical credentialing , with the influx of ... ... 29, 2009 -- According to an article from the Journal of General Internal Medicine, ...
... , ... national leader in deliciously healthy, ready to heat and eat meals, are applauding the ... weight loss is all about portion-controlled, properly balanced meals. , ... Lorton, VA (PRWEB) August 29, 2009 -- Officials at Diet-to-Go, ...
Cached Medicine News:Health News:Researchers identify protein involved in causing gum disease, osteoporosis, arthritis 2Health News:Researchers identify protein involved in causing gum disease, osteoporosis, arthritis 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 4Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 5Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 6Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 7Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 8Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 9Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 2Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 3Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 4Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 5Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 6Health News:Alcohol Ads on Cable TV Reach Young Audiences 2Health News:Alcohol Ads on Cable TV Reach Young Audiences 3Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 2Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 3Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 2Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: